Medical Pharmacology: Chapter 9: Antianginal Drugs -- Module 5: Ranolazine, Ivabradine & Other Newer Antianginal Agents

Chapter 9: Antianginal Drugs — Module 5: Ranolazine, Ivabradine & Other Newer Antianginal Agents

1. A 64-year-old man with chronic stable angina is on ranolazine 1000 mg twice daily, metoprolol succinate 100 mg daily, and amlodipine 10 mg daily with good anginal control and a baseline QTc of 438 ms. He develops community-acquired pneumonia and his primary care physician prescribes clarithromycin 500 mg twice daily for 7 days. The patient asks his cardiologist whether it is safe to continue both medications during the antibiotic course. Which of the following is the most appropriate response?

A) The combination is safe because ranolazine and clarithromycin act through entirely different mechanisms with no pharmacokinetic interaction; the patient should complete the full antibiotic course at standard doses without any modification to his cardiac regimen
B) The combination requires monitoring but is manageable; the patient should obtain a repeat ECG at day 3 of the antibiotic course and discontinue clarithromycin only if QTc exceeds 520 ms, otherwise continuing both drugs to completion
C) Clarithromycin is a strong CYP3A4 inhibitor that increases ranolazine plasma levels 3.5- to 4.5-fold; this magnitude of exposure increase substantially raises the risk of QTc prolongation and torsades de pointes; concurrent use is contraindicated in the ranolazine prescribing information; clarithromycin should not be prescribed and an alternative antibiotic that does not strongly inhibit CYP3A4 — such as amoxicillin-clavulanate or doxycycline depending on organism sensitivity — should be selected
D) The patient should reduce his ranolazine dose to 500 mg twice daily for the duration of the clarithromycin course and resume 1000 mg twice daily after completing the antibiotic; dose reduction is the standard management for all CYP3A4 inhibitor interactions with ranolazine
E) The combination is safe if the patient avoids grapefruit juice during the antibiotic course, as grapefruit is a more potent CYP3A4 inhibitor than clarithromycin and is the primary dietary source of clinically significant CYP3A4 inhibition affecting ranolazine levels

ANSWER: C

Rationale:

Clarithromycin is a prototypical strong CYP3A4 inhibitor. Ranolazine is primarily metabolized by CYP3A4, and strong inhibition of this pathway raises ranolazine plasma AUC by 3.5- to 4.5-fold — a degree of exposure amplification that substantially increases the risk of dose-dependent QTc prolongation and torsades de pointes (TdP). The FDA prescribing information for ranolazine lists co-administration with strong CYP3A4 inhibitors (including clarithromycin, ketoconazole, and ritonavir) as a contraindication — not a dose-adjustment scenario. The distinction between strong and moderate CYP3A4 inhibitors is clinically critical: for moderate inhibitors (diltiazem, verapamil, erythromycin, fluconazole), ranolazine dose should be limited to 500 mg twice daily with QTc monitoring; for strong inhibitors, no dose of ranolazine is safe during concurrent use, and the co-administration is contraindicated. The correct management is to select an alternative antibiotic. For community-acquired pneumonia, appropriate alternatives that do not strongly inhibit CYP3A4 include amoxicillin-clavulanate, doxycycline, or — if atypical coverage is required — azithromycin (a weaker CYP3A4 inhibitor than clarithromycin, used with caution).

Option A: Option A is incorrect — a major pharmacokinetic interaction exists through CYP3A4 inhibition.
Option B: Option B is incorrect — serial ECG monitoring does not make a contraindicated drug combination safe; by the time QTc reaches 520 ms, the patient is already at elevated risk of TdP.
Option D: Option D is incorrect — dose reduction to 500 mg BID is the management for moderate CYP3A4 inhibitors, not strong ones; strong inhibitor co-administration is contraindicated regardless of ranolazine dose.
Option E: Option E is incorrect — while grapefruit is a CYP3A4 inhibitor, it is less potent than clarithromycin in terms of systemic CYP3A4 inhibition; the primary interaction concern here is clarithromycin, and grapefruit avoidance does not resolve a contraindicated drug combination.

2. A cardiologist reviews four patients with stable angina to determine which is the best candidate for ivabradine. Patient A: 68-year-old man, HFrEF (EF 33%), permanent atrial fibrillation, resting ventricular rate 82 bpm, on digoxin and carvedilol 12.5 mg twice daily. Patient B: 71-year-old woman, preserved EF, sinus rhythm, resting HR 54 bpm, on metoprolol succinate 25 mg daily (lowest tolerated dose due to fatigue). Patient C: 59-year-old man, preserved EF, sinus rhythm, resting HR 76 bpm, on metoprolol succinate 200 mg daily (maximum dose), baseline QTc 508 ms. Patient D: 65-year-old woman, HFrEF (EF 31%), sinus rhythm, resting HR 78 bpm, on carvedilol 25 mg twice daily (maximum tolerated dose), with stable angina causing three episodes per week. Which patient is the most appropriate candidate for ivabradine initiation?

A) Patient A, because the elevated ventricular rate of 82 bpm in the context of HFrEF indicates inadequate rate control, and ivabradine's rate-dependent HCN channel blockade is more effective at higher rates, making this the ideal physiological scenario for the drug
B) Patient B, because her preserved ejection fraction and sinus rhythm meet the basic eligibility criteria for ivabradine, and the low metoprolol dose suggests room for pharmacodynamic complementarity without risk of excessive bradycardia from the combination
C) Patient C, because the resting heart rate of 76 bpm on maximum metoprolol dose meets the HR eligibility criterion, and QTc prolongation is not a contraindication for ivabradine since the drug does not affect ventricular repolarization
D) Patient A and Patient D equally, because both have HFrEF with inadequate rate control, and ivabradine is indicated for all HFrEF patients with resting heart rate above 70 bpm regardless of cardiac rhythm
E) Patient D, who has HFrEF (EF 31%, meeting the ≤35% threshold), confirmed sinus rhythm, resting heart rate 78 bpm (meeting the ≥70 bpm threshold), and is on maximum tolerated carvedilol dose — satisfying all SHIFT trial eligibility criteria; she also has concurrent stable angina that ivabradine will address simultaneously; Patient A is disqualified by permanent atrial fibrillation (absolute contraindication); Patient B is disqualified by resting HR of 54 bpm (absolute contraindication — HR must be ≥60 bpm at initiation); Patient C is disqualified by baseline QTc of 508 ms, which, while not a direct contraindication for ivabradine itself, should prompt extreme caution given the need for QTc monitoring

ANSWER: E

Rationale:

Ivabradine eligibility requires satisfying all mandatory criteria simultaneously. For the HFrEF indication (SHIFT trial basis): EF ≤35%, sinus rhythm, resting HR ≥70 bpm, on maximally tolerated beta-blocker. Patient D satisfies every criterion: EF 31% (≤35% ✓), sinus rhythm (✓), resting HR 78 bpm (≥70 ✓), carvedilol 25 mg BID documented as maximum tolerated dose (✓). Her concurrent stable angina is additionally addressed by ivabradine, making a single drug serve two indications — the optimal scenario. Patient A is disqualified by permanent atrial fibrillation, which is an absolute contraindication to ivabradine: HCN channels are specific to the sinoatrial node, and ivabradine provides no ventricular rate control in AF; prescribing it in AF is pharmacologically futile and clinically inappropriate regardless of ventricular rate or HFrEF status. Patient B is disqualified by resting HR of 54 bpm, which is below the absolute contraindication threshold of <60 bpm; initiating ivabradine in a patient with HR already at 54 bpm risks symptomatic or dangerous bradycardia. Patient C presents a complex situation: sinus rhythm and HR 76 bpm on maximum metoprolol would ordinarily qualify for the angina indication; however, a baseline QTc of 508 ms is markedly elevated. While ivabradine itself does not prolong QTc (one of its advantages), a QTc this elevated warrants thorough investigation of cause and extreme caution before adding any cardiac drug — Patient D remains the clearly superior candidate with no disqualifying factors.

Option A: Option A is incorrect — Patient A's permanent AF is an absolute contraindication; ventricular rate and HFrEF status do not override this.
Option B: Option B is incorrect — Patient B's resting HR of 54 bpm is below the absolute contraindication threshold of <60 bpm.
Option C: Option C is incorrect — while QTc is not a direct contraindication for ivabradine, the clinical judgment favors Patient D who has no disqualifying factors and meets all positive criteria.
Option D: Option D is incorrect — Patient A is disqualified by permanent AF; HFrEF status alone does not establish eligibility.

3. A 77-year-old man with permanent atrial fibrillation, HFpEF (heart failure with preserved ejection fraction), and stable angina is on digoxin 0.125 mg daily (steady-state level 0.7 ng/mL), furosemide 40 mg daily, and bisoprolol 5 mg daily. His cardiologist adds ranolazine 1000 mg twice daily for persistent angina. Three weeks later he presents with anorexia, nausea, and a resting ventricular rate of 34 bpm. His ECG shows complete AV block with a junctional escape rhythm. His digoxin level is 2.4 ng/mL. Serum potassium is 3.8 mmol/L. Which of the following best explains the mechanism of this presentation and the correct immediate management?

A) Ranolazine directly blocks AV nodal L-type calcium channels at therapeutic concentrations, adding pharmacodynamic AV nodal depression to the rate-slowing effect of digoxin; the correct management is to discontinue both drugs immediately and initiate temporary cardiac pacing if the patient is hemodynamically unstable
B) Ranolazine inhibits P-glycoprotein (P-gp), a drug transporter that normally limits intestinal absorption and promotes renal tubular secretion of digoxin; P-gp inhibition raises digoxin plasma levels approximately 1.5-fold at standard ranolazine doses; in this patient the digoxin level has risen from 0.7 to 2.4 ng/mL (a 3.4-fold increase, suggesting additional contributing factors such as reduced renal clearance or dehydration from furosemide); the immediate management is to withhold digoxin, provide cardiac monitoring and hemodynamic support, and assess and correct renal function and electrolytes; temporary pacing should be available if the escape rhythm is inadequate
C) Ranolazine inhibits CYP3A4, which is responsible for approximately 40% of digoxin hepatic metabolism; the resulting reduction in digoxin clearance raises plasma levels and causes toxicity; the management is to reduce the ranolazine dose to 500 mg twice daily and allow digoxin levels to fall passively over 48-72 hours
D) The elevated digoxin level and AV block are caused by ranolazine-induced acute kidney injury through inhibition of renal tubular organic anion transporters, reducing glomerular filtration and impairing digoxin elimination; the management is intravenous fluid resuscitation to restore renal function and allow digoxin clearance
E) The presentation reflects pharmacodynamic synergy between ranolazine's QTc-prolonging effect and digoxin's vagotonic AV nodal slowing, which together have produced complete heart block; the correct management is to administer intravenous atropine to reverse the vagotonic component and reduce the ranolazine dose to eliminate QTc-mediated AV conduction slowing

ANSWER: B

Rationale:

This clinical scenario illustrates the ranolazine-digoxin P-glycoprotein interaction compounded by additional patient-specific factors. Ranolazine inhibits P-glycoprotein (P-gp), an efflux transporter that plays dual roles in digoxin pharmacokinetics: in the intestine, P-gp limits bioavailability by pumping digoxin back into the gut lumen; in the renal tubule, P-gp actively secretes digoxin into the urine, contributing substantially to its elimination. Inhibition of both processes by ranolazine raises steady-state digoxin levels by approximately 1.5-fold. In this patient, the digoxin level rose from 0.7 to 2.4 ng/mL — a 3.4-fold increase — substantially exceeding the expected 1.5-fold pharmacokinetic prediction. This discrepancy likely reflects additive contributions: furosemide-induced volume depletion may have reduced renal blood flow and glomerular filtration, further impairing digoxin's predominantly renal elimination. The resulting digoxin toxicity produced enhanced vagal AV nodal suppression and direct cardiac membrane effects causing complete AV block. Immediate management requires: withholding digoxin (not dose-reducing ranolazine alone, which would not rapidly normalize digoxin levels); cardiac monitoring with hemodynamic support; ECG monitoring; assessment of renal function and correction of any electrolyte disturbances (hypokalemia and hypomagnesemia potentiate digoxin toxicity); and readiness to initiate temporary cardiac pacing if the junctional escape rhythm is inadequate to maintain perfusion. Digoxin-specific antibody fragments (Digibind/DigiFab) should be considered if the patient is hemodynamically unstable.

Option A: Option A is incorrect — ranolazine does not block AV nodal L-type calcium channels; the toxicity is digoxin-mediated.
Option C: Option C is incorrect — digoxin is not significantly metabolized by CYP3A4; its primary elimination is renal excretion mediated by P-gp.
Option D: Option D is incorrect — ranolazine does not cause acute kidney injury through tubular transporter inhibition; the renal contribution in this case is more likely furosemide-related volume depletion impairing GFR.
Option E: Option E is incorrect — ranolazine's mild QTc prolongation does not produce AV block; QTc prolongation reflects delayed ventricular repolarization, not AV conduction slowing; and atropine alone would not be appropriate management for complete heart block from digoxin toxicity.

4. A 73-year-old woman in the United Kingdom with stable angina has been on nicorandil 20 mg twice daily for 22 months. She presents to her gastroenterologist with a 10-week history of painful oral ulcers on the buccal mucosa and a concurrent large ulcer on the perianal skin that has not responded to topical corticosteroids. Colonoscopy to the terminal ileum is normal. Biopsy of the perianal ulcer shows non-specific chronic inflammation with no granulomas, no dysplasia, and no evidence of malignancy. HIV serology, herpes simplex virus PCR, and CMV testing are all negative. The gastroenterologist diagnoses Behçet disease and plans to initiate immunosuppression. Which of the following represents the most important step that should occur before initiating immunosuppression?

A) Obtain anti-neutrophil cytoplasmic antibody (ANCA) serology and a small bowel MRI to complete the Behçet disease diagnostic workup before committing to immunosuppression, as ANCA positivity would suggest an alternative vasculitic diagnosis requiring different therapy
B) Perform HLA-B51 genetic testing, as a positive result is required to confirm a diagnosis of Behçet disease before initiating systemic immunosuppression in a patient whose mucocutaneous pattern does not include pathergy or uveitis
C) Obtain an urgent dermatology opinion for patch testing to identify a contact allergen responsible for the oral and perianal ulceration before attributing the presentation to a systemic inflammatory condition
D) Review the patient's complete medication list; nicorandil — a dual-mechanism antianginal agent combining KATP channel opening and nitrate-like activity — is a well-documented cause of mucocutaneous ulceration affecting the oral mucosa, gastrointestinal tract, and perianal region that can precisely mimic Behçet disease or inflammatory bowel disease; nicorandil should be discontinued and the ulcers reassessed after cessation before committing to immunosuppression, as the ulcers typically heal after drug withdrawal
E) Initiate a 6-week trial of colchicine at 0.5 mg twice daily, the standard first-line treatment for Behçet disease mucocutaneous manifestations, before considering nicorandil as a contributing factor, since drug-induced ulceration from nicorandil is a rare phenomenon requiring prospective confirmation with rechallenge before it can be accepted as the diagnosis

ANSWER: D

Rationale:

This case illustrates one of the most clinically important diagnostic pitfalls associated with nicorandil: its ability to cause mucocutaneous ulceration that closely mimics inflammatory bowel disease (particularly Crohn's disease with perianal involvement) and Behçet disease. Nicorandil-induced mucocutaneous ulceration is a well-documented adverse effect producing large, painful, slow-healing ulcers that can affect the oral mucosa, esophagus, small bowel, colon, perianal region, and skin. The mechanism is poorly understood and unrelated to either of nicorandil's pharmacological mechanisms. The diagnostic workup performed — colonoscopy, biopsy, infectious serology — has appropriately excluded malignancy, infection, and Crohn's disease but has not addressed medication causality. Before initiating systemic immunosuppression, which carries its own risks including infection, malignancy, and bone marrow suppression, the critical step is medication review and nicorandil discontinuation. After stopping nicorandil, the ulcers typically heal completely over weeks to months — confirming the diagnosis retrospectively and sparing the patient unnecessary immunosuppression. Rechallenge to confirm the diagnosis is not required and would be inappropriate given the severity of the adverse effect.

Option A: Option A is incorrect — while completing the diagnostic workup is reasonable, ANCA testing is more relevant to ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis) and would not be the most important next step given the clear drug exposure history.
Option B: Option B is incorrect — HLA-B51 testing supports but is not required for a clinical Behçet diagnosis, and more importantly, a positive result would not change the imperative to first exclude drug causality.
Option C: Option C is incorrect — contact dermatitis does not cause internal mucocutaneous ulcers at multiple sites including oral mucosa and perianal region; patch testing is not the priority here.
Option E: Option E is incorrect — the instruction to treat Behçet disease before investigating nicorandil as a cause imposes unnecessary risk; the correct sequence is always to identify and remove potential causative drugs before initiating immunosuppression.

5. A 74-year-old man in France has been on trimetazidine 35 mg twice daily for stable angina for 4 years. He is referred to neurology for a 9-month history of resting tremor in his right hand, cogwheel rigidity on passive elbow movement, and a shuffling gait with reduced arm swing. His neurologist orders brain MRI (normal) and dopamine transporter (DaT) SPECT imaging, which shows normal bilateral striatal uptake. The neurologist initially diagnoses idiopathic Parkinson's disease and plans to initiate levodopa-carbidopa. Before doing so, he asks a clinical pharmacologist colleague for a second opinion. What is the most important issue the pharmacologist should raise?

A) Trimetazidine is a recognized cause of drug-induced parkinsonism through interference with dopaminergic signaling pathways; the normal DaT scan is the critical diagnostic finding, as it indicates intact dopaminergic nigrostriatal neurons and rules against idiopathic Parkinson's disease (in which DaT uptake is reduced due to neurodegeneration); the correct management is to discontinue trimetazidine and observe for symptom resolution over weeks to months before initiating levodopa; in 2012, the EMA restricted trimetazidine's indications specifically because of this neurological adverse effect and excluded patients with movement disorders from its approved use
B) Trimetazidine causes Parkinson-like symptoms exclusively through mitochondrial complex I inhibition in dopaminergic substantia nigra neurons — the same mechanism as MPTP neurotoxicity — producing irreversible nigrostriatal cell death; the normal DaT scan is a false negative because DaT SPECT has insufficient sensitivity to detect early-stage cell loss; levodopa-carbidopa should be initiated urgently alongside trimetazidine discontinuation
C) The neurological findings are unrelated to trimetazidine because the drug's mechanism of action — inhibition of mitochondrial 3-KAT in cardiac myocytes — is compartmentalized to cardiac tissue and cannot produce neurological adverse effects; the DaT scan result confirms structural dopaminergic integrity consistent with idiopathic Parkinson's disease, and levodopa should be initiated as planned
D) The correct diagnosis is drug-induced parkinsonism from bisoprolol — a beta-blocker known to cross the blood-brain barrier and inhibit central dopaminergic transmission — rather than trimetazidine; the pharmacologist should recommend switching to a beta-blocker with lower CNS penetrance such as atenolol before attributing the neurological syndrome to trimetazidine
E) The normal DaT scan excludes any medication-related cause of the parkinsonian syndrome, as drug-induced parkinsonism from any agent always produces reduced DaT uptake due to the drug's direct effect on presynaptic dopamine transporter expression; the presentation should be attributed to atypical Parkinsonism such as progressive supranuclear palsy and workup should proceed accordingly

ANSWER: A

Rationale:

The clinical scenario presents the defining diagnostic challenge of trimetazidine-induced parkinsonism: the symptom triad (resting tremor, cogwheel rigidity, shuffling gait) is indistinguishable clinically from idiopathic Parkinson's disease, but the dopamine transporter (DaT) SPECT scan result is the pivotal differentiating finding. In idiopathic Parkinson's disease, progressive degeneration of nigrostriatal dopaminergic neurons reduces the density of presynaptic dopamine transporters in the striatum, producing the characteristic asymmetric or bilateral reduction in DaT uptake visible on SPECT imaging. In drug-induced parkinsonism — including that caused by trimetazidine — the dopaminergic neurons are not degenerating; they remain structurally intact. The DaT scan is therefore normal, as in this patient. This normal DaT finding should immediately prompt reassessment of the diagnosis and a systematic medication review. Trimetazidine has been established as a cause of drug-induced parkinsonism, believed to result from interference with dopaminergic signaling (possibly through inhibition of dopamine metabolism or receptor interactions) without causing actual nigrostriatal neurodegeneration. This adverse effect was the primary basis for the European Medicines Agency's 2012 restriction of trimetazidine indications, which excluded patients with movement disorders. The correct management is discontinuation of trimetazidine followed by observation: the parkinsonian symptoms are generally reversible after cessation, though recovery may take weeks to months for established cases. Initiating levodopa-carbidopa before discontinuing the causative drug would mask the response to drug withdrawal and expose the patient to unnecessary treatment with its own adverse effect profile.

Option B: Option B is incorrect — trimetazidine does not cause irreversible nigrostriatal cell death analogous to MPTP; and DaT SPECT is sensitive enough to detect early-stage nigrostriatal loss — a normal result genuinely reflects intact neurons.
Option C: Option C is incorrect — trimetazidine's neurological adverse effects are well-documented and cannot be dismissed; normal DaT scanning does not confirm idiopathic Parkinson's disease, it excludes nigrostriatal neurodegeneration.
Option D: Option D is incorrect — bisoprolol does not cause parkinsonism; beta-blockers are not a recognized cause of dopaminergic parkinsonism, though they can cause tremor through beta-adrenergic mechanisms that is distinct from parkinsonian tremor.
Option E: Option E is incorrect — this inverts the diagnostic logic; drug-induced parkinsonism from trimetazidine and other dopamine-blocking agents characteristically produces a normal DaT scan, not a reduced one; reduced DaT is the signature of idiopathic Parkinson's disease.

6. A 61-year-old woman with stable angina and HFrEF (EF 34%) was started on ivabradine 5 mg twice daily six weeks ago. At follow-up she reports that approximately three to four times per week she experiences sudden bright flashes and colorful halos in her visual field lasting 30-60 seconds, consistently triggered when she walks from a brightly lit room into a dimly lit corridor or when she encounters oncoming headlights while driving at night. She is alarmed by these episodes and has already stopped driving after dark. Ophthalmological examination including fundoscopy is entirely normal. Which of the following best explains this adverse effect and guides the management discussion?

A) The visual phenomena represent transient ischemic episodes affecting the occipital cortex caused by ivabradine-induced excessive bradycardia reducing cerebral perfusion; urgent Holter monitoring and carotid Doppler ultrasonography should be performed before the next dose of ivabradine is taken
B) The patient is experiencing migraine with visual aura triggered by ivabradine's effect on central serotonergic pathways; ivabradine should be discontinued immediately and replaced with a triptan-compatible antianginal agent such as ranolazine
C) The patient is experiencing phosphenes — a recognized and class-specific adverse effect of ivabradine occurring in approximately 14-18% of treated patients; the mechanism is HCN channel blockade in retinal cells (HCN channels are expressed in both sinoatrial node pacemaker cells and the retina), which alters light-adaptation signaling and produces transient luminous visual phenomena triggered by sudden changes in light intensity; the phenomena are completely benign, do not reflect retinal or cerebral pathology, and are fully reversible with dose reduction or discontinuation; the patient's decision to avoid night driving is clinically prudent given the distraction these phenomena cause; management options include reassurance, dose reduction to 2.5 mg twice daily, or discontinuation if the phenomena are intolerable
D) The visual phenomena are caused by ivabradine-induced hypotension from excessive heart rate reduction, producing transient retinal hypoperfusion; blood pressure measurement at the next visit is required and the ivabradine dose should be reduced until resting systolic BP is above 100 mmHg
E) The patient is experiencing drug-induced macular degeneration from ivabradine's HCN channel blockade in retinal pigment epithelium cells, an irreversible adverse effect requiring immediate ophthalmological referral for intravitreal anti-VEGF therapy and permanent discontinuation of all HCN-blocking agents

ANSWER: C

Rationale:

This patient's presentation is a textbook description of ivabradine-induced phosphenes. The cardinal features are all present: onset within the first weeks to months of therapy, transient luminous visual phenomena (bright flashes and halos) of short duration (seconds), consistent triggering by sudden changes in light intensity (light-to-dark transitions, oncoming headlights), and normal ophthalmological examination. The mechanism is the expression of HCN (hyperpolarization-activated cyclic nucleotide-gated) channels in retinal cells, where If currents play a role in photoreceptor signal processing and light adaptation. Ivabradine's HCN channel blockade disrupts this retinal signaling, producing the characteristic visual phenomena. The incidence is approximately 14-18% in clinical trials — substantially higher than with placebo — confirming the drug-effect relationship. Three points are essential for management: first, phosphenes are completely benign and do not represent retinal ischemia, macular pathology, or cerebral pathology; they reflect a pharmacodynamic off-target effect of HCN blockade in the retina. Second, they are fully reversible on dose reduction or discontinuation. Third, and critically from a safety standpoint, this patient has already made the clinically appropriate decision to stop driving after dark — episodes of bright visual phenomena triggered by oncoming headlights represent a genuine driving hazard, and this counseling point must be reinforced explicitly for all patients before ivabradine is initiated. Management options in order of escalation: reassurance and observation if tolerable; dose reduction to 2.5 mg twice daily; or discontinuation if the phenomena are intolerable or recur on dose reduction.

Option A: Option A is incorrect — phosphenes are not caused by cerebral ischemia; a normal ophthalmological examination and the characteristic light-triggered pattern make this diagnosis; Holter and carotid Doppler are not indicated.
Option B: Option B is incorrect — ivabradine does not affect serotonergic pathways; the visual phenomena are not migraine aura; the trigger pattern (light-intensity changes, not preceded by headache or scotoma progression) is distinctive.
Option D: Option D is incorrect — the visual phenomena are not caused by retinal hypoperfusion; blood pressure is not the relevant parameter; phosphenes occur at therapeutic heart rates without hypotension.
Option E: Option E is incorrect — ivabradine does not cause macular degeneration; the phenomena are transient and fully reversible, the antithesis of irreversible macular disease; anti-VEGF therapy is entirely inappropriate.

7. A 71-year-old woman with stable angina graded CCS class III has been on bisoprolol 10 mg daily and amlodipine 10 mg daily for 18 months. She continues to have three to four anginal episodes per week. Her resting heart rate is 50 bpm and blood pressure is 102/66 mmHg. She is in sinus rhythm and her ECG shows no conduction abnormalities. Her renal function is normal and baseline QTc is 424 ms. Her cardiologist considers adding a third antianginal agent. Which of the following is the most pharmacologically appropriate choice?

A) Isosorbide mononitrate 30 mg daily with a mandatory 10-12 hour nitrate-free interval, because the nitrate-free interval will prevent tolerance and the low starting dose will minimize the risk of additional hypotension
B) Diltiazem ER 120 mg once daily, because as a non-dihydropyridine calcium channel blocker it adds both rate-slowing and vasodilatory antianginal benefit through a mechanism distinct from bisoprolol and amlodipine
C) Ivabradine 5 mg twice daily, because the patient is in sinus rhythm and the resting heart rate of 50 bpm, while at the lower boundary, does not strictly disqualify her since ivabradine's rate-dependent mechanism will have minimal effect at this heart rate and therefore will not cause significant further bradycardia
D) Verapamil ER 240 mg once daily, because unlike diltiazem its predominant vasodilatory effect at standard doses minimizes the risk of AV block when added to an existing beta-blocker regimen and provides superior preload reduction compared to amlodipine
E) Ranolazine 500 mg twice daily, titrated to 1000 mg twice daily as tolerated; ranolazine's mechanism — selective inhibition of the late inward sodium current (late INa) in cardiac myocytes — reduces myocardial ischemia without any effect on heart rate, blood pressure, or contractility; it is the appropriate agent when hemodynamic reserve is fully exhausted by conventional therapy, as in this patient where resting HR of 50 bpm and BP of 102/66 mmHg preclude all hemodynamic antianginal options

ANSWER: E

Rationale:

This patient illustrates the prototypical clinical scenario for ranolazine: hemodynamic exhaustion on maximally tolerated conventional dual therapy. A systematic review of each alternative reveals why all hemodynamic options are contraindicated or inappropriate in this specific patient. Ivabradine (Option C): absolute contraindication is resting HR <60 bpm before initiation; this patient's resting HR is 50 bpm, which falls clearly below this threshold; Option C's reasoning that rate-dependent mechanism prevents further bradycardia is pharmacologically imprecise and does not override the prescribing contraindication. Isosorbide mononitrate (Option A): organic nitrates reduce preload through venodilation, lowering venous return and blood pressure; adding a nitrate to a patient with resting BP of 102/66 mmHg risks symptomatic hypotension, presyncope, and syncope, particularly when combined with amlodipine's vasodilatory effect; even a low starting dose in this hemodynamic context is inappropriate. Diltiazem (Option B): as a non-dihydropyridine CCB with significant AV nodal slowing effects, adding diltiazem to bisoprolol (a beta-blocker) creates a high-risk combination for bradycardia, AV block, and complete heart block — particularly hazardous in a patient already at HR 50 bpm. Verapamil (Option D): identical concern to diltiazem; verapamil is the more potent AV nodal depressant of the two non-dihydropyridine CCBs; co-administration with a beta-blocker at HR 50 bpm risks hemodynamic collapse; the claim that verapamil is safer than diltiazem with beta-blockers is incorrect — both are contraindicated in this combination at these hemodynamic parameters. Ranolazine is the correct choice: its exclusively non-hemodynamic mechanism (late INa inhibition at the myocyte level) provides additive anti-ischemic benefit with zero effect on HR, BP, or AV conduction. The starting dose of 500 mg BID with titration to 1000 mg BID is appropriate, with QTc monitoring given the new drug initiation.

Option A: Option A is incorrect — nitrate addition risks symptomatic hypotension at BP 102/66 mmHg.
Option B: Option B is incorrect — diltiazem combined with bisoprolol at HR 50 bpm risks AV block.
Option C: Option C is incorrect — resting HR 50 bpm is an absolute contraindication to ivabradine initiation.
Option D: Option D is incorrect — verapamil combined with beta-blocker at HR 50 bpm is contraindicated.

8. A 58-year-old man with stable angina and preserved left ventricular function (EF 58%) in sinus rhythm has a resting heart rate of 74 bpm on metoprolol succinate 200 mg daily. His cardiologist initiates ivabradine and, aiming for maximum heart rate reduction, prescribes 7.5 mg twice daily. A pharmacist reviewing the prescription asks the cardiologist to reconsider the dose. Which of the following best explains the pharmacist's concern and the correct prescribing decision?

A) Ivabradine 7.5 mg twice daily exceeds the maximum approved dose for all indications; the absolute dose ceiling across all ivabradine indications is 5 mg twice daily regardless of the clinical context, and a dose of 7.5 mg has never been studied in any clinical trial at any indication
B) The SIGNIFY trial, which enrolled over 19,000 patients with stable coronary artery disease without heart failure, demonstrated that in the prespecified subgroup of patients with angina receiving ivabradine 7.5 mg twice daily, the incidence of the primary endpoint — cardiovascular death or nonfatal myocardial infarction — was significantly increased compared to placebo; as a regulatory consequence, most prescribing guidelines and product labels now cap ivabradine at 5 mg twice daily for the stable angina indication in patients without heart failure, and 7.5 mg twice daily should not be prescribed in this patient
C) The dose of 7.5 mg twice daily is appropriate for stable angina and is the standard target dose recommended by ESC guidelines; the pharmacist's concern is likely based on an outdated package insert that predates the 2019 ESC Chronic Coronary Syndromes guidelines, which upgraded ivabradine 7.5 mg BID to a Class I recommendation for stable angina with resting HR above 70 bpm
D) The pharmacist is concerned about QTc prolongation; ivabradine 7.5 mg twice daily produces clinically significant QTc prolongation of approximately 25-30 ms above baseline, substantially increasing the risk of torsades de pointes; the dose should be reduced to 5 mg twice daily, at which the QTc effect is below 5 ms and considered clinically negligible
E) The dose of 7.5 mg twice daily is appropriate for this patient if his resting heart rate remains above 70 bpm at the 2-week follow-up visit; the pharmacist's concern reflects a conservative institutional protocol, but published evidence supports uptitration to 7.5 mg twice daily when 5 mg twice daily achieves insufficient heart rate reduction in patients with preserved ejection fraction and stable angina

ANSWER: B

Rationale:

The SIGNIFY trial (Fox et al., 2014) enrolled 19,102 patients with stable coronary artery disease without heart failure who had resting heart rate ≥70 bpm on standard background therapy. Participants were randomized to ivabradine or placebo. The trial used a higher starting dose than prior HF trials: in the angina subgroup, patients received ivabradine 7.5 mg twice daily (or 10 mg twice daily in some protocol variants). The overall primary endpoint — cardiovascular death or nonfatal myocardial infarction — was not significantly reduced; and in the prespecified subgroup of patients with angina receiving the higher ivabradine dose, primary endpoint event rates were significantly higher in the ivabradine arm than in the placebo arm. This safety signal was not observed in the HFrEF population studied in SHIFT (where 7.5 mg BID was used successfully), suggesting that the harm signal may be population-specific. The regulatory consequence was important: most regulatory agencies and prescribing guidelines subsequently capped ivabradine for the stable angina indication in patients without heart failure at 5 mg twice daily. The 7.5 mg twice daily dose should not be used in this clinical context — this is the exact patient profile studied in SIGNIFY (stable angina, preserved EF, no HF), and the evidence specifically associates harm with this dose in this population.

Option A: Option A is incorrect — 7.5 mg twice daily is not above the absolute dose ceiling for all indications; it is used in HFrEF patients in the SHIFT trial and remains appropriate in that context; the concern is population-specific, not a universal dose ceiling.
Option C: Option C is incorrect — ESC 2019 guidelines do not recommend 7.5 mg BID for stable angina without HF; the dose constraint is a post-SIGNIFY safety measure incorporated into current guidelines.
Option D: Option D is incorrect — ivabradine does not prolong QTc; this is one of its established advantages; QTc prolongation is not the pharmacist's concern.
Option E: Option E is incorrect — uptitration to 7.5 mg BID for insufficient HR reduction at 5 mg BID is not supported for stable angina without HF; the SIGNIFY safety data specifically cautions against this strategy in this population.

9. A 63-year-old man with type 2 diabetes (HbA1c 8.3% on metformin 1000 mg twice daily and sitagliptin 100 mg daily), stable angina, and preserved LV function has a resting heart rate of 66 bpm and blood pressure of 136/82 mmHg. He is on bisoprolol 10 mg daily and amlodipine 10 mg daily. He continues to have two to three anginal episodes per week. His endocrinologist is considering adding a third antidiabetic agent; his cardiologist is considering adding a third antianginal agent. They discuss which addition would provide benefit across both conditions simultaneously. Which of the following best describes the agent and mechanistic rationale for a single pharmacological addition that addresses both inadequate anginal control and suboptimal glycemic control in this patient?

A) Ivabradine 5 mg twice daily; ivabradine reduces heart rate through HCN channel blockade in the sinoatrial node and also inhibits glucagon secretion from pancreatic alpha cells through HCN channel blockade in islet cells, producing complementary antianginal and antidiabetic effects without hypoglycemia risk
B) A GLP-1 receptor agonist such as semaglutide; semaglutide reduces HbA1c by 1.0-1.5% and has documented cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease, including reduction of major adverse cardiovascular events; it can serve as the third antidiabetic agent while providing cardiovascular risk reduction, addressing both conditions simultaneously
C) Nicorandil 10 mg twice daily; nicorandil's KATP channel-opening mechanism in pancreatic beta cells mimics the glucose-stimulated insulin secretion response and lowers HbA1c by approximately 0.8% at standard doses, while its nitrate-like component provides antianginal venodilation; the combination addresses both conditions through a single dual-mechanism agent
D) Ranolazine 1000 mg twice daily; ranolazine inhibits late INa not only in cardiac myocytes — reducing myocardial ischemia without altering heart rate or blood pressure — but also in pancreatic beta cells, where the same mechanism reduces glucotoxic intracellular calcium overload and improves glucose-stimulated insulin secretion, producing an average HbA1c reduction of approximately 0.5% at 1000 mg twice daily without causing hypoglycemia; ranolazine thus serves simultaneously as the third antianginal agent and provides meaningful glycemic benefit in a patient whose HbA1c is already 8.3% on dual oral therapy
E) Empagliflozin 10 mg daily; empagliflozin is an SGLT2 inhibitor with proven cardiovascular mortality reduction in patients with type 2 diabetes and established cardiovascular disease, and it also reduces myocardial ischemia by shifting cardiac metabolism toward ketone body oxidation, directly mimicking the anti-ischemic metabolic shift produced by trimetazidine and providing both glycemic and antianginal benefit

ANSWER: D

Rationale:

Ranolazine is the agent that most precisely and mechanistically addresses both of this patient's therapeutic gaps through a single shared mechanism. Its cardiac anti-ischemic action — selective inhibition of late INa in cardiac myocytes, reducing intracellular Na+ and Ca2+ overload during ischemia — operates without any effect on heart rate (already adequate at 66 bpm), blood pressure, or contractility, making it appropriate at this hemodynamic profile. Its glycemic effect extends from the same mechanistic target: late INa is expressed in pancreatic beta cells, where chronic hyperglycemia (glucotoxicity) causes pathological late INa increase, driving Ca2+ overload that impairs insulin secretion. Ranolazine's inhibition of late INa in beta cells reduces this glucotoxic calcium overload and restores glucose-stimulated insulin secretion, producing an HbA1c reduction of approximately 0.5% at 1000 mg twice daily — without causing hypoglycemia, because the mechanism enhances physiological insulin release rather than forcing secretion independent of glucose. In a patient at HbA1c 8.3% already on metformin and sitagliptin, adding ranolazine could bring HbA1c toward the 7.5-7.8% range while simultaneously improving anginal control.

Option A: Option A is incorrect — ivabradine does not affect pancreatic HCN channels at therapeutic concentrations in a clinically meaningful way for glycemic control; ivabradine has no established antidiabetic effect.
Option B: Option B is incorrect — while GLP-1 receptor agonists are valuable in type 2 diabetes with cardiovascular disease, they are not antianginal agents in the mechanistic sense; they do not reduce anginal symptoms through an established anti-ischemic mechanism; they address different therapeutic targets and would require separate antianginal therapy.
Option C: Option C is incorrect — nicorandil has no established antidiabetic effect; pancreatic beta cell KATP channel opening does not improve insulin secretion in the way described; opening KATP channels in beta cells actually hyperpolarizes and inhibits insulin secretion (the opposite of the described effect).
Option E: Option E is incorrect — while empagliflozin has documented cardiovascular mortality benefit in type 2 diabetes with CVD, it does not reduce anginal episodes through a direct anti-ischemic mechanism; its cardiovascular benefit is predominantly through volume effects and hemodynamic offloading rather than myocardial ischemia reduction; the claim that it mimics trimetazidine's metabolic shift is an oversimplification not established as a mechanism for angina relief.

10. A 67-year-old man with HFrEF (EF 32%) and stable angina has been on carvedilol 25 mg twice daily, sacubitril/valsartan, eplerenone, and ivabradine 5 mg twice daily for 10 months, with resting heart rate well-controlled at 58-62 bpm and good anginal symptom control. He presents to the emergency department with palpitations and fatigue of 18 hours duration. His ECG shows atrial fibrillation with a ventricular rate of 112 bpm. He is hemodynamically stable. The emergency physician asks the cardiology team which of the patient's current medications requires immediate reassessment in the context of new AF. Which of the following represents the correct management decision regarding ivabradine?

A) Ivabradine must be discontinued immediately; its mechanism — selective HCN channel blockade in the sinoatrial node — has no effect on AV nodal conduction and therefore provides no ventricular rate control in atrial fibrillation; continuing ivabradine in AF exposes the patient to phosphene risk, CYP3A4 drug interactions, and potential adverse effects without any anti-arrhythmic or rate-controlling benefit; rate control for the new AF should be managed by uptitrating carvedilol, adding digoxin, or using other AV nodal-slowing agents as appropriate for his HFrEF
B) Ivabradine should be continued at the current dose because its rate-dependent HCN channel blockade becomes more effective at higher ventricular rates, and the ventricular rate of 112 bpm will amplify ivabradine's channel-blocking efficiency in the AV node, providing meaningful rate control during the acute AF episode
C) Ivabradine should be continued at reduced dose (2.5 mg twice daily) because partial If channel blockade provides residual benefit by slowing SA node firing and reducing the frequency of sinoatrial impulses that compete with the AF wavefronts, reducing the overall ventricular rate through a rate-competition mechanism
D) Ivabradine should be increased to 7.5 mg twice daily in the context of the new AF, because higher HCN channel blockade reduces the rate of spontaneous depolarizations that sustain atrial fibrillation wavefronts, facilitating spontaneous cardioversion to sinus rhythm within 24-48 hours
E) Ivabradine can be continued for 48 hours to assess whether the elevated ventricular rate spontaneously decreases as the HCN channel blockade progressively occupies AV nodal HCN channels at the higher heart rate; if the ventricular rate remains above 100 bpm after 48 hours, the drug should then be discontinued

ANSWER: A

Rationale:

The development of atrial fibrillation is a mandatory indication to discontinue ivabradine, for two compounding reasons that are both pharmacologically absolute. First, the mechanistic reason: ivabradine's target — HCN channels conducting the funny current (If) — is expressed in sinoatrial node pacemaker cells, where it drives spontaneous phase 4 depolarization and controls the heart rate in sinus rhythm. In atrial fibrillation, the sinoatrial node is suppressed by chaotic atrial electrical activity and is not generating the cardiac rhythm. Ventricular rate in AF is determined entirely by how much of the chaotic atrial activity conducts through the AV node — a process mediated by L-type calcium channels and AV nodal refractoriness, not by HCN channels. Ivabradine has no pharmacological activity at AV nodal tissue at therapeutic concentrations. Therefore, ivabradine provides zero ventricular rate control in AF regardless of dose. Second, the safety reason: continuing a drug that provides no benefit while maintaining full exposure to its adverse effects (phosphenes, CYP3A4 interactions with the patient's existing polypharmacy, and any bradycardia risk if sinus rhythm spontaneously restores) is pharmacologically unjustifiable. The correct approach for ventricular rate control in this patient with HFrEF and new AF is to use AV nodal-slowing agents: uptitrating carvedilol (already present in the regimen) is often the first step; adding digoxin is appropriate in HFrEF with AF given its concurrent positive inotropic effect; non-dihydropyridine CCBs (diltiazem, verapamil) are generally avoided in HFrEF due to negative inotropic effects. Options B, C, D, and E all perpetuate the fundamental error of assuming ivabradine has some mechanism of action in AF — this is pharmacologically impossible given the drug's target specificity.

11. A 69-year-old man in Australia with stable angina CCS class III has been on bisoprolol 10 mg daily, amlodipine 10 mg daily, and isosorbide mononitrate 60 mg daily (with a mandatory 12-hour nitrate-free interval) for 14 months. He continues to have two to three anginal episodes per week. His resting heart rate is 58 bpm and blood pressure is 128/78 mmHg. His cardiologist — in a jurisdiction where nicorandil is available — considers adding nicorandil 10 mg twice daily. A colleague raises the concern that the patient's existing nitrate therapy may limit nicorandil's efficacy. Which of the following best characterizes the pharmacological basis for this concern and whether the combination remains worthwhile?

A) The concern is unfounded because nicorandil and isosorbide mononitrate act through entirely separate mechanisms with no pharmacological overlap; nicorandil's KATP channel-opening mechanism and the organic nitrate's guanylyl cyclase activation are completely independent pathways that cannot cross-tolerate, and the combination provides fully additive benefit across all of nicorandil's pharmacological components
B) The concern is valid and the combination should be avoided entirely; cross-tolerance between nicorandil and organic nitrates is complete and bidirectional, meaning that a patient already on isosorbide mononitrate will derive no benefit whatsoever from nicorandil's addition because both the KATP component and the nitrate component of nicorandil become tolerance-resistant in the presence of established nitrate therapy
C) The concern is pharmacologically valid but does not preclude benefit from the combination; nicorandil's nitrate-like component — which releases NO to activate soluble guanylyl cyclase and raise cyclic GMP, producing venodilation — shares the same downstream signaling machinery that undergoes tolerance with continuous organic nitrate exposure, meaning the venodilating (preload-reducing) benefit of nicorandil's nitrate component may be attenuated in this nitrate-tolerant patient; however, nicorandil's KATP channel-opening mechanism — which produces coronary and peripheral arteriolar vasodilation through membrane hyperpolarization — and its mitochondrial KATP-mediated cardioprotective preconditioning effect are entirely independent of the NO-cGMP pathway and remain fully active; the combination therefore still offers additive anti-ischemic benefit through nicorandil's non-nitrate mechanisms even in a patient with established nitrate tolerance
D) The concern is valid, and the correct management is to discontinue isosorbide mononitrate before starting nicorandil; a 48-hour nitrate washout period is sufficient to fully restore guanylyl cyclase sensitivity, after which nicorandil can be initiated at full dose with complete efficacy of both its KATP and nitrate-like components
E) The concern is only relevant if the patient has been on isosorbide mononitrate continuously without a nitrate-free interval; because this patient uses a 12-hour nitrate-free interval, guanylyl cyclase sensitivity is fully restored each day during the drug-free period, and nicorandil will achieve complete efficacy of its nitrate-like venodilating component during the hours when isosorbide mononitrate plasma levels are low

ANSWER: C

Rationale:

This question requires precise understanding of nicorandil's dual mechanism and the selective nature of nitrate cross-tolerance. Nicorandil operates through two distinct pharmacological mechanisms: a nitrate-like NO-releasing component that activates soluble guanylyl cyclase (sGC) to generate cyclic GMP (cGMP) and produce venodilation (identical downstream pathway to organic nitrates), and a KATP channel-opening component that acts independently of NO-cGMP to produce coronary and peripheral vasodilation through K+ efflux and membrane hyperpolarization, along with mitochondrial KATP-mediated cardioprotective preconditioning. Nitrate tolerance — the reduced vasodilatory response to continuous nitrate exposure — develops at the level of sGC and related cGMP signaling components. Because nicorandil's nitrate-like component uses this same sGC-cGMP machinery, cross-tolerance is pharmacologically established: a patient tolerant to isosorbide mononitrate will have a blunted response to nicorandil's venodilating (preload-reducing) effect. Cross-tolerance is notably less complete than with pure nitrates, possibly because nicorandil's KATP-driven vasodilation partially maintains vascular tone reduction independent of the NO-cGMP pathway. Critically, KATP channel opening — both vascular and mitochondrial — is entirely independent of sGC and cGMP and is therefore completely unaffected by nitrate tolerance. The KATP-mediated coronary vasodilation, arteriolar afterload reduction, and mitochondrial preconditioning remain fully functional in a nitrate-tolerant patient. The combination therefore retains meaningful clinical utility: the KATP mechanisms provide additive anti-ischemic benefit beyond what isosorbide mononitrate achieves, even if the shared venodilation pathway adds less than expected.

Option A: Option A is incorrect — the NO-cGMP pathway is shared between nicorandil's nitrate-like component and organic nitrates; cross-tolerance is pharmacologically established and the claim of no overlap is false.
Option B: Option B is incorrect — cross-tolerance is not complete and does not affect the KATP mechanisms; the claim that no benefit whatsoever is obtainable is false.
Option D: Option D is incorrect — 48-hour nitrate washout does not reliably or completely restore sGC sensitivity in a patient on long-term nitrate therapy; and the framing that cross-tolerance is completely reversible with brief washout is an oversimplification.
Option E: Option E is incorrect — a 12-hour nitrate-free interval reduces but does not eliminate nitrate tolerance in patients on chronic nitrate therapy; sGC sensitivity does not fully restore within hours of the nitrate-free period in all patients; the claim of complete efficacy restoration is pharmacologically inaccurate.